The sharp profitability deterioration and cash burn suggest the growth investments are not yet translating to operating leverage. Monitor Q2 2026 for evidence of sales productivity and margin recovery. The S-3 overhang (5.6M shares) adds supply risk. The $22.9M contracted revenue provides some visibility but implies back-half weighting that may disappoint if execution falters.
Price Chart
Executive Summary
Health In Tech reported Q1 2026 revenue of $8.8M (+9.4% YoY) but swung to a net loss of $1.6M (-$0.03/diluted share) from net income of $0.5M in Q1 2025, with Adjusted EBITDA turning negative at -$1.3M vs +$1.2M a year ago. The company reiterated its 2026 revenue guidance of $45M-$50M, but the sharp deterioration in profitability and operating cash flow burn of -$3.3M raise concerns about the cost of its growth investments.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $8.77M, up 9.4% YoY from $8.01M
- Net loss of $1.59M (-$0.03/diluted) vs net income of $0.50M ($0.01/diluted) in Q1 2025
- Adjusted EBITDA turned negative to -$1.29M from +$1.23M in Q1 2025
- Operating cash flow was -$3.32M vs +$0.53M in Q1 2025
- Gross profit declined to $4.51M from $5.36M, gross margin compressed to 51.4% from 66.8%
- Sales & marketing expenses doubled to $2.29M from $1.09M
- Cash balance $10.3M, boosted by $6.4M net from March PIPE financing
- 2026 full-year revenue guidance reiterated at $45M-$50M; contracted revenue for remaining 3 quarters is $22.9M
- S-3 shelf filed 19 days ago for up to 5.6M shares by selling stockholders
Financial Impact
Revenue grew 9.4% but net income swung from +$0.5M to -$1.6M; Adjusted EBITDA fell from +$1.2M to -$1.3M; operating cash flow reversed from +$0.5M to -$3.3M
Risk Factors
- S-3 shelf registration allows selling stockholders to sell up to 5.6M shares, creating overhang
- Operating cash flow deeply negative at -$3.3M; cash burn may require additional capital
- Sales & marketing spend doubled with no near-term profitability payoff
- Revenue guidance of $45M-$50M requires 35%-50% YoY growth; Q1 growth was only 9.4%
- Contracted revenue of $22.9M for remaining 3 quarters implies $14.5M-$19.5M must come from new business
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055824 |
| Document: ea0290619-8k_health.htm | 0001213900-26-055824 |
| Document: 0001213900-26-055824-index-headers.html | 0001213900-26-055824 |
| Document: 0001213900-26-055824-index.html | 0001213900-26-055824 |
| Document: 0001213900-26-055824.txt | 0001213900-26-055824 |
| 8-K Data (Synthetic) | 0001213900-26-055824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 22, 2026 3d ago | 3 | $0.5623 | awaiting T+60 | — | $0.5359 (−4.70%) |
Oct 16, 2026 10d ago | 8-K | $0.6350 | awaiting T+60 | — | $0.5359 (+15.61%) |
Oct 16, 2026 10d ago | EFFECT | $0.6520 | awaiting T+60 | — | $0.5359 (+17.81%) |
Oct 13, 2026 13d ago | DEF 14A | $0.6780 | awaiting T+60 | — | $0.5359 (+20.96%) |
Oct 9, 2026 16d ago | S-3/A | $0.7200 | awaiting T+60 | — | $0.5359 (+25.57%) |
Sep 30, 2026 26d ago | Press Release | $0.7380 | awaiting T+60 | — | $0.5359 (−27.38%) |
Sep 29, 2026 27d ago | SC 13G | $0.8525 | awaiting T+60 | — | $0.5359 (−37.14%) |
Sep 4, 2026 7w ago | S-3 | $0.9801 | awaiting T+60 | — | $0.5359 (+45.32%) |
Aug 13, 2026 10w ago | Press Release | $1.01 | awaiting T+60 | — | $0.5359 (+46.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers